Enliven Therapeutics, Inc. - Common Stock (ELVN)

46.71
-1.40 (-2.91%)
NASDAQ · Last Trade: Apr 20th, 3:48 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
Issued on behalf of Oncolytics Biotech Inc.
By Equity Insider · Via GlobeNewswire · January 12, 2026
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END
Via FinancialNewsMedia · October 4, 2024